Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2008 1
2009 1
2010 3
2011 2
2012 6
2013 7
2014 1
2015 4
2016 8
2017 8
2018 5
2019 4
2020 5
2021 6
2022 9
2023 3
2024 1
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: ito k. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D. Okazawa-Sakai M, et al. Among authors: ito k. J Gynecol Oncol. 2025 May;36(3):e38. doi: 10.3802/jgo.2025.36.e38. Epub 2024 Oct 21. J Gynecol Oncol. 2025. PMID: 39453391 Free PMC article.
The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer.
Miyoshi A, Isohashi F, Fujii M, Iwamiya T, Takemura M, Nagase Y, Yokoi T, Yoshioka E, Ito K, Yamabe E, Masuhara K, Tsujie T, Kimura T, Kodama M. Miyoshi A, et al. Among authors: ito k. Int J Gynaecol Obstet. 2025 Aug;170(2):908-915. doi: 10.1002/ijgo.70077. Epub 2025 Mar 22. Int J Gynaecol Obstet. 2025. PMID: 40119600 Free PMC article.
Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study.
Tanaka T, Takehara K, Usami T, Ishikawa M, Kondo E, Kagabu M, Hirabayashi K, Matsumura N, Sato S, Nishimura M, Arakawa A, Nakamura K, Konno Y, Fujiwara S, Sueoka K, Nakamura H, Koh I, Ito K, Hongo A. Tanaka T, et al. Among authors: ito k. Gynecol Oncol Rep. 2025 Apr 9;59:101740. doi: 10.1016/j.gore.2025.101740. eCollection 2025 Jun. Gynecol Oncol Rep. 2025. PMID: 40297564 Free PMC article.
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).
Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T, Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E, Nishio K, Matsumura N. Fukuda N, et al. Among authors: ito k. Int J Clin Oncol. 2026 Feb;31(2):310-318. doi: 10.1007/s10147-025-02942-8. Epub 2025 Dec 22. Int J Clin Oncol. 2026. PMID: 41430003
Synchronous primary malignancies in ovarian cancer and liver angiosarcoma.
Taguchi T, Egawa-Takata T, Kunimoto S, Nagano T, Yoshimura M, Haruna K, Shinke G, Ohmura Y, Ito K. Taguchi T, et al. Among authors: ito k. Gynecol Oncol Rep. 2022 Sep 29;44:101073. doi: 10.1016/j.gore.2022.101073. eCollection 2022 Dec. Gynecol Oncol Rep. 2022. PMID: 36217325 Free PMC article.
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K, Nakagawa M, Shimokawa M, Hori K, Tashima L, Goto M, Yanagida S, Suzuki J, Kaya R, Kawabata A, Yamada K, Park J, Nasu H, Nishio S, Kondo E, Kaneda M, Tsubamoto H, Arakawa A, Nagasawa T, Motohashi T. Ito K, et al. Anticancer Drugs. 2023 Aug 1;34(7):857-865. doi: 10.1097/CAD.0000000000001472. Epub 2022 Dec 5. Anticancer Drugs. 2023. PMID: 36729915 Clinical Trial.
72 results